Journey Medical Corporation Announces Positive Comparative Pharmacokinetic (PK) Data for DFD-29

December 20, 2022

https://www.globenewswire.com/news-release/2022/12/20/2577082/0/en/Journey-Medical-Corporation-Announces-Positive-Comparative-Pharmacokinetic-PK-Data-for-DFD-29.html

SCOTTSDALE, Ariz., Dec. 20, 2022 (GLOBE NEWSWIRE) — Journey Medical Corporation (NASDAQ:DERM) (“Journey Medical”), a commercial-stage biopharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions, today announced positive PK comparability data of DFD-29 and key updates on the progress of its pivotal, Phase 3 clinical study of DFD-29 for the treatment of papulopustular rosacea in collaboration with Dr. Reddy’s Laboratories Ltd. (“Dr. Reddy’s”).

Read more at globenewswire.com

Related news for (DERM)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.